NDA 020837 · Hikma
Xopenex
Levalbuterol Hydrochloride · Inhalation
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 3, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Mar 25, 1999
Approved uses
3
Original approval plus efficacy supplements
Registered trials
793
238 Phase 3, 24 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 22, 2015 Supplement 41 · Efficacy LetterPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Jan 30, 2002 Supplement 6 · Efficacy Label
- Mar 25, 1999 Original approval · Type 3 - New Dosage Form LabelReviewLetter
4 products under this application
- XOPENEX · LEVALBUTEROL HYDROCHLORIDE EQ 0.0103% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued · TE AN
- XOPENEX · LEVALBUTEROL HYDROCHLORIDE EQ 0.021% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued · TE AN
- XOPENEX · LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued · TE AN
- XOPENEX · LEVALBUTEROL HYDROCHLORIDE EQ 0.042% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INHALATION · Discontinued · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Levalbuterol" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03769090 · 3,132 participants · Start Dec 13, 2018 · Primary completion Aug 19, 2021
Drug: Albuterol sulfate metered-dose inhaler 180 μg · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 345 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.
Jat KR, Khairwa A · Pulm Pharmacol Ther 2013 · Comparative Study, Meta-Analysis
- Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma.
Handley DA, Tinkelman D, Noonan M, et al. · J Asthma 2000 · Clinical Trial, Comparative Study
- Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma.
Nelson HS, Bensch G, Pleskow WW, et al. · J Allergy Clin Immunol 1998 · Clinical Trial, Comparative Study
- Effect of levalbuterol on prehospital patient parameters.
Rodenberg H · Am J Emerg Med 2002 · Clinical Trial, Controlled Clinical Trial
- Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children.
Hardasmalani MD, DeBari V, Bithoney WG, et al. · Pediatr Emerg Care 2005 · Comparative Study, Randomized Controlled Trial
- Levalbuterol is as effective as racemic albuterol in lowering serum potassium.
Pancu D, LaFlamme M, Evans E, et al. · J Emerg Med 2003 · Clinical Trial, Comparative Study
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.